Cognition Therapeutics, Inc. CGTX 深 沪
交易中 04-01 10:43:41 美东时间
0.8147
+0.055
+7.27%
华盛通- 最 高0.88
- 今 开0.80
- 成交量 98.29万股
- 最 低 0.7736
- 昨 收 0.7595
- 总市值 7279.65万
- 52周最高 3.83
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 0.2223
- 委 比 66.67%
- 总股本 8935.38万
- 历史最高 13.80
- 量 比 1.97
- 振 幅 14.01%
- 历史最低 0.2223
- 每 手 1
- 风险率 0.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cognition Therapeutics shares are trading lower. The company reported Q4 financial results.
Cognition Therapeutics shares are trading lower. The company reported Q4 financ...
03-27 23:53
Cognition Therapeutics Q4 EPS $(0.01) Beats $(0.05) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.05) by 80 percent. This is a 94.12 percent increase over losses of $(0.17) per share
03-26 19:32
Earnings Scheduled For March 26, 2026
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
Cognition Therapeutics Presents Analysis From Phase 2 COG1201 SHIMMER Study Of Zervimesine In Dementia With Lewy Bodies At AD/PD 2026 Alzheimer's & Parkinson's Diseases Conference
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study
03-17 19:35
Cognition Therapeutics Extends Duration Of Expanded Access Program For Dementia With Lewy Bodies
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded access program
02-05 20:40
Cognition Therapeutics Meets With FDA to Plan Mid-Stage Trial for Lewy Body Dementia Drug
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food and Drug
01-27 20:37
Cognition Therapeutics Study On Phase 2 Trial Of Zervimesine In Patients With Mild-to-Moderate Dementia With Lewy Bodies Meets Primary Endpoint Of Safety, Tolerability
Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, "Phase 2 Study of Zervimesine (CT1812) in Participants with Mild-to-Moderate Dementia with Lewy Bodies (DLB)" (doi:
01-06 20:36
Cognition Therapeutics Presented Plans For Registrational Program For Zervimesine In Mild-To-Moderate Alzheimer's Disease
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented plans for a registrational program for zervimesine in
2025-12-01 20:40
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
B. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3
B. Riley Securities analyst William Woods reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and raises the price target from $2 to $3.
2025-11-22 00:10
